cMyBPC phosphorylation modulates the effect of omecamtiv mecarbil on myocardial force generation

Strategies for targeting the cardiac sarcomere: avenues for novel drug discovery

(2020) Joshua B. Holmes et al.   Expert Opinion on Drug Discovery

Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction

(2020) John R. Teerlink et al.   JACC-Heart Failure

Cardiomyocyte slowly activating delayed rectifier potassium channel: regulation by exercise and β-adrenergic signaling

(2020) Xinrui Wang et al.   JOURNAL OF APPLIED PHYSIOLOGY

AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC deficient mice

(2020) Jiayang Li et al.   JCI Insight

Omecamtiv Mecarbil in Chronic Heart Failure with Reduced Ejection Fraction, GALACTIC‐HF : Baseline Characteristics and Comparison with Contemporary Clinical Trials

(2020) John R. Teerlink et al.   EUROPEAN JOURNAL OF HEART FAILURE

Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations

(2019) James A. Spudich   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

The HCM-causing Y235S cMyBPC mutation accelerates contractile function by altering C1 domain structure

(2019) Chang Yoon Doh et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Cardiac Calcitropes, Myotropes, and Mitotropes

(2019) Mitchell A. Psotka et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin

(2019) James W. McNamara et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials

(2019) Tariq Ahmad et al.   EUROPEAN JOURNAL OF HEART FAILURE

Sarcomere-based genetic enhancement of systolic cardiac function in a murine model of dilated cardiomyopathy

(2018) Jiayang Li et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Impact of the Myosin Modulator Mavacamten on Force Generation and Cross‐Bridge Behavior in a Murine Model of Hypercontractility

(2018) Ranganath Mamidi et al.   Journal of the American Heart Association

Inotropic interventions do not change the resting state of myosin motors during cardiac diastole

(2018) Marco Caremani et al.   JOURNAL OF GENERAL PHYSIOLOGY

Cardiac Disorders and Pathophysiology of Sarcomeric Proteins

(2018) Jolanda van der Velden et al.   PHYSIOLOGICAL REVIEWS

Lost in translation: Interpreting cardiac muscle mechanics data in clinical practice

(2018) Ranganath Mamidi et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Omecamtiv Mecarbil Enhances the Duty Ratio of Human β-Cardiac Myosin Resulting in Increased Calcium Sensitivity and Slowed Force Development in Cardiac Muscle

(2017) Anja M. Swenson et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament

(2017) Thomas Kampourakis et al.   JOURNAL OF PHYSIOLOGY-LONDON

Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke

(2017) John A. Rohde et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cardiac myosin binding protein-C Ser302phosphorylation regulates cardiac β-adrenergic reserve

(2017) Ranganath Mamidi et al.   Science Advances

The myosin activator omecamtiv mecarbil: a promising new inotropic agent

(2016) Péter Nánási et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

The contributions of cardiac myosin binding protein C and troponin I phosphorylation to β-adrenergic enhancement ofin vivocardiac function

(2016) Kenneth S. Gresham et al.   JOURNAL OF PHYSIOLOGY-LONDON

Cardiac Myosin Binding Protein-C Phosphorylation Modulates Myofilament Length-Dependent Activation

(2016) Ranganath Mamidi et al.   Frontiers in Physiology

Omecamtiv Mecarbil Modulates the Kinetic and Motile Properties of Porcine β-Cardiac Myosin

(2015) Yingying Liu et al.   BIOCHEMISTRY

Phosphorylation of Cardiac Myosin-Binding Protein-C Is a Critical Mediator of Diastolic Function

(2015) P. C. Rosas et al.   Circulation-Heart Failure

Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C

(2015) Ranganath Mamidi et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina

(2015) Barry H. Greenberg et al.   JACC-Heart Failure

Analytical Comparison of Natural and Pharmaceutical Ventricular Myosin Activators

(2014) Yihua Wang et al.   BIOCHEMISTRY

The contribution of cardiac myosin binding protein-c Ser282 phosphorylation to the rate of force generation andin vivocardiac contractility

(2014) Kenneth S. Gresham et al.   JOURNAL OF PHYSIOLOGY-LONDON

Structure, sarcomeric organization, and thin filament binding of cardiac myosin-binding protein-C

(2014) Roger Craig et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Length-dependent changes in contractile dynamics are blunted due to cardiac myosin binding protein-C ablation

(2014) Ranganath Mamidi et al.   Frontiers in Physiology

Characterization of the cardiac myosin binding protein-C phosphoproteome in healthy and failing human hearts

(2013) Viola Kooij et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Cardiac Myosin Binding Protein C and Its Phosphorylation Regulate Multiple Steps in the Cross-Bridge Cycle of Muscle Contraction

(2012) Arthur T. Coulton et al.   BIOCHEMISTRY

Myosin binding protein-C phosphorylation is the principal mediator of protein kinase A effects on thick filament structure in myocardium

(2012) Brett A. Colson et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

cMyBP-C as a promiscuous substrate: phosphorylation by non-PKA kinases and its potential significance

(2011) Sonya C. Bardswell et al.   JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

(2011) John GF Cleland et al.   LANCET

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

(2011) John R Teerlink et al.   LANCET

Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure

(2011) F. I. Malik et al.   SCIENCE

Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure

(2010) You-Tang Shen et al.   Circulation-Heart Failure

Model representation of the nonlinear step response in cardiac muscle

(2010) Steven J. Ford et al.   JOURNAL OF GENERAL PHYSIOLOGY

Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle

(2010) O'Neal Copeland et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Differential roles of regulatory light chain and myosin binding protein-C phosphorylations in the modulation of cardiac force development

(2010) Brett A. Colson et al.   JOURNAL OF PHYSIOLOGY-LONDON

Nebulin Alters Cross-bridge Cycling Kinetics and Increases Thin Filament Activation

(2009) Murali Chandra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Acceleration of Crossbridge Kinetics by Protein Kinase A Phosphorylation of Cardiac Myosin Binding Protein C Modulates Cardiac Function

(2008) Carl W. Tong et al.   CIRCULATION RESEARCH

Protein Kinase A–Mediated Phosphorylation of cMyBP-C Increases Proximity of Myosin Heads to Actin in Resting Myocardium

(2008) Brett A. Colson et al.   CIRCULATION RESEARCH

Myosin binding protein C phosphorylation in normal, hypertrophic and failing human heart muscle

(2008) Adam M. Jacques et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY